Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19 2* loss of function polymorphism

International Journal of Cardiology

Volumn 145, Issue 1, 2010, Pages 165-166

  Bonello, Laurent ^a   Palot Bonello, Nathalie ^b   Armero, Sébastien ^a   Camoin Jau, Laurence ^c   Paganelli, Franck ^a  

^a HÔPITAL NORD   (France)

^b TIMONE HOSPITAL   (France)

^c INSERM   (France)

Author keywords

Clopidogrel; Cytochrome polymorphism; Platelet reactivity monitoring; Thrombosis; VASP index

Indexed keywords

CLOPIDOGREL;

ACUTE CORONARY SYNDROME; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DOSIMETRY; FEMALE; GENETIC POLYMORPHISM; HIGH RISK PATIENT; HOMOZYGOTE; HUMAN; LETTER; LOADING DRUG DOSE; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; THROMBOCYTE FUNCTION; THROMBOSIS;

EID: 78049465814     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2009.07.033     Document Type: Article

References (9)

1. J.P. Collet, J.S. Hulot, and A. Pena Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
2. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
3. D. Sibbling, J. Stegherr, and W. Latz Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention Eur Heart J 30 2009 916 922
4. S.M. de Morais, G.R. Wilkinson, J. Blaisdell, K. Nakamura, U.A. Meyer, and J.A. Goldstein The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans J Biol Chem 269 1994 15419 15422
5. L. Bonello, L. Camoin-Jau, and S. Armero Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis Am J Cardiol 103 2009 5 10
6. L. Bonello, L. Camoin-Jau, and S. Arques Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study J Am Coll Cardiol 51 2008 1404 1411
7. L. Bonello, F. Paganelli, and M. Arpin-Bornet Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events J Thromb Haemost 5 2007 1630 1636
8. R. Blindt, K. Stellbrink, and A. de Taeye The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis Thromb Haemost 98 2007 1329 1334
9. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150